Stopped: Enrollment was extremely low and there were too many adverse events.
1. Evaluate differences between patients taking Duloxetine or placebo following lateral lumbar interbody fusion for postoperative narcotic consumption. 2. Evaluate differences between patients taking Duloxetine or placebo following lateral lumbar interbody fusion for postoperative pain, function, and quality of life. 3. Evaluate the correlation between preoperative screening tests (measuring pain centralization, anxiety, depression, and overall function) and patients' response to treatment (reduction in pain, anxiety, or depression and improvement in function).
Age range
24 Years – 99 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Evaluating the amount of change in pain, for patients prescribed Duloxetine versus those patients prescribed the placebo following lateral lumbar interbody fusion
Timeframe: The study medication (either placebo or Duloxetine) will be continued throughout the duration of hospitalization. Remaining pills will be provided to the patient as a discharge prescription to allow for 10 days total treatment.
Measuring the amount of change in pain, for patients prescribed Duloxetine versus those patients prescribed the placebo following lateral lumbar interbody fusion
Timeframe: The study medication (either placebo or Duloxetine) will be continued throughout the duration of hospitalization. Remaining pills will be provided to the patient as a discharge prescription to allow for 10 days total treatment.
Evaluating the amount of change in function for patients prescribed Duloxetine versus those patients prescribed the placebo following lateral lumbar interbody fusion
Timeframe: The study medication (either placebo or Duloxetine) will be continued throughout the duration of hospitalization. Remaining pills will be provided to the patient as a discharge prescription to allow for 10 days total treatment.
Measuring the amount of change in function for patients prescribed Duloxetine versus those patients prescribed the placebo following lateral lumbar interbody fusion
Timeframe: The study medication (either placebo or Duloxetine) will be continued throughout the duration of hospitalization. Remaining pills will be provided to the patient as a discharge prescription to allow for 10 days total treatment.
Evaluating the amount of change in narcotic consumption for patients prescribed Duloxetine versus those patients prescribed the placebo following lateral lumbar interbody fusion
Timeframe: The study medication (either placebo or Duloxetine) will be continued throughout the duration of hospitalization. Remaining pills will be provided to the patient as a discharge prescription to allow for 10 days total treatment.
Measuring the amount of change in narcotic consumption for patients prescribed Duloxetine versus those patients prescribed the placebo following lateral lumbar interbody fusion
Timeframe: The study medication (either placebo or Duloxetine) will be continued throughout the duration of hospitalization. Remaining pills will be provided to the patient as a discharge prescription to allow for 10 days total treatment.
Measuring the general domains of health with PROMIS Global questionnaire
Timeframe: Patients will be asked to complete the PROMIS Global at baseline visit
Measuring the general domains of function with PROMIS Global questionnaire
Timeframe: Patients will be asked to complete the PROMIS Global at baseline visit
Measuring the general domains of health with PROMIS Global questionnaire
Timeframe: Patients will be asked to complete the PROMIS Global at 2 week post-op visit
Measuring the general domains of function with PROMIS Global questionnaire
Timeframe: Patients will be asked to complete the PROMIS Global at 2 week post-op visit
Measuring the general domains of health with PROMIS Global questionnaire
Timeframe: Patients will be asked to complete the PROMIS Global at 4 week post-op visit
Measuring the general domains of function with PROMIS Global questionnaire
Timeframe: Patients will be asked to complete the PROMIS Global at 4 week post-op visit
Measuring the general domains of health with PROMIS Global questionnaire
Timeframe: Patients will be asked to complete the PROMIS Global at 8 week post-op visit
Measuring the general domains of function with PROMIS Global questionnaire
Timeframe: Patients will be asked to complete the PROMIS Global at 8 week post-op visit
Patient's anxiety symptoms severity at baseline visit
Timeframe: Patients will be asked to complete the GAD-7 at the baseline visit
Patient's anxiety symptoms severity at eight week visit
Timeframe: Patients will be asked to complete the GAD-7 at the 8 week post-op visit.
Measuring a patient's baseline visit for severity of depression symptoms with Beck's Depression Inventory
Timeframe: Patient s will complete the Beck's Depression Inventory at the baseline visit.
Measuring a patient's eight week visit for severity of depression symptoms with Beck's Depression Inventory
Timeframe: Patient s will complete the Beck's Depression Inventory at the 8 week post-op visit.
Measuring at the baseline of a patient's hypersensitivity to noxious and non-noxious stimuli with the Central Sensitization Inventory
Timeframe: Patients will complete the Central Sensitization Inventory at the baseline visit.
Measuring at eight weeks to evaluate a patient's hypersensitivity to noxious and non-noxious stimuli with the Central Sensitization Inventory
Timeframe: Patients will complete the Central Sensitization Inventory at the 8 week post-op visit.
Baseline to measure a patient's catastrophic thinking in relation to adults with or without chronic pain.
Timeframe: The patient will complete the Pain Catastrophizing Scale at the baseline visit.
Eight week measurement of a patient's catastrophic thinking in relation to adults with or without chronic pain.
Timeframe: The patient will complete the Pain Catastrophizing Scale at the 8 week post-op visit.
Two week evaluation of amount of change in post-op pain improvement
Timeframe: Patients to be evaluated at post-op at 2 weeks.
Four week evaluation of amount of change in post-op pain improvement
Timeframe: Patients to be evaluated at post-op at 4 weeks.
Eight week evaluataion of amount of change in post-op pain improvement
Timeframe: Patients to be evaluated at post-op at 8 weeks.
Two week evaluation of amount of change in post-op quality of life improvement
Timeframe: Patients to be evaluated at post-op at 2 weeks
Four week evaluation of amount of change in post-op quality of life improvement
Timeframe: Patients to be evaluated at post-op at 4 weeks.
Eight week evaluation of amount of change in post-op quality of life improvement
Timeframe: Patients to be evaluated at post-op at 8 weeks.